⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Pin1–cis P-tau Axis
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2025-12-05 — The immuno-neurological axis: association between autoimmune diseases and dementia risk.: cross-connection with immunosenescence: Autoimmune-disease-associated dementia risk (especially Alzheimer’s) in this cohort connects age-related immune dysregulation to the tau/Alzheimer’s mechanistic axis, bridging the immune-aging roster to a specific CNS proteostasis pathway. (novelty: 3)
- 2026-09-12 — Soluble pathogenic tau transmission to astrocytes drives acute oxidative damage, cellular senescence, and neurovascular uncoupling in a model of Alzheimers tauopathy: cross-connection with cellular-senescence: Adds astrocytes as a cell type in which pathogenic tau species drive a senescence program, complementing the Pin1–cis P-tau axis’s neuron-centric view of tau-driven aging pathology. (novelty: 3)
- 2026-09-12 — The Pin1-cis P-tau Axis: A Key Common Early Pathogenic Driver, Biomarker and Therapeutic Target Across Neurodegenerative, Traumatic, and Vascular Cognitive Disorders.: 2026 review-level synthesis positions the Pin1–cis P-tau axis as a shared early pathogenic driver, biomarker, and cis-specific immunotherapy target across neurodegenerative, traumatic (TBI/CTE), and vascular cognitive disorders, extending the axis beyond conventional tauopathies but adding no new primary human readout. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
The Pin1-cis P-tau Axis: A Key Common Early Pathogenic Driver, Biomarker and Therapeutic Target Across Neurodegenerative, Traumatic, and Vascular Cognitive Disorders.
12-sep-2026
novelty 3
per-area 3
strengthens